Literature DB >> 19164291

TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein.

Takayuki Murata1, Yoshitaka Sato, Sanae Nakayama, Ayumi Kudoh, Satoko Iwahori, Hiroki Isomura, Masako Tajima, Takayuki Hishiki, Takayuki Ohshima, Makoto Hijikata, Kunitada Shimotohno, Tatsuya Tsurumi.   

Abstract

Reactivation of the Epstein-Barr virus from latency is dependent on expression of the viral BZLF1 protein. The BZLF1 promoter (Zp) normally exhibits only low basal activity but is activated in response to chemical inducers such as 12-O-tetradecanoylphorbol-13-acetate and calcium ionophore. We found here that Transducer of Regulated cAMP-response Element-binding Protein (CREB) (TORC) 2 enhances Zp activity 10-fold and more than 100-fold with co-expression of the BZLF1 protein. Mutational analysis of Zp revealed that the activation by TORC is dependent on ZII and ZIII cis elements, binding sites for CREB family transcriptional factors and the BZLF1 protein, respectively. Immunoprecipitation, chromatin immunoprecipitation, and reporter assay using Gal4-luc and Gal4BD-BZLF1 fusion protein indicate that TORC2 interacts with BZLF1, and that the complex is efficiently recruited onto Zp. These observations clearly indicate that TORC2 activates the promoter through interaction with the BZLF1 protein as well as CREB family transcriptional factors. Induction of the lytic replication resulted in the translocation of TORC2 from cytoplasm to viral replication compartments in nuclei, and furthermore, activation of Zp by TORC2 was augmented by calcium-regulated phosphatase, calcineurin. Silencing of endogenous TORC2 gene expression by RNA interference decreased the levels of the BZLF1 protein in response to 12-O-tetradecanoylphorbol-13-acetate/ionophore. Based on these results, we conclude that Epstein-Barr virus exploits the calcineurin-TORC signaling pathway through interactions between TORC and the BZLF1 protein in reactivation from latency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164291      PMCID: PMC2658097          DOI: 10.1074/jbc.M808466200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter.

Authors:  N Taylor; E Flemington; J L Kolman; R P Baumann; S H Speck; G Miller
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA.

Authors:  K Takada; K Horinouchi; Y Ono; T Aya; T Osato; M Takahashi; S Hayasaka
Journal:  Virus Genes       Date:  1991-04       Impact factor: 2.332

3.  TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.

Authors:  Ali I Kuraishy; Samuel W French; Mara Sherman; Marco Herling; Dan Jones; Randolph Wall; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

4.  Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2.

Authors:  Renaud Dentin; Yi Liu; Seung-Hoi Koo; Susan Hedrick; Thomas Vargas; Jose Heredia; John Yates; Marc Montminy
Journal:  Nature       Date:  2007-09-05       Impact factor: 49.962

5.  Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1.

Authors:  E Flemington; S H Speck
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression.

Authors:  Kim Ravnskjaer; Henri Kester; Yi Liu; Xinmin Zhang; Dong Lee; John R Yates; Marc Montminy
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

7.  BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function.

Authors:  Thomas E Morrison; Shannon C Kenney
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

8.  Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125.

Authors:  Kei-ichiro Arimoto; Hitoshi Takahashi; Takayuki Hishiki; Hideyuki Konishi; Takashi Fujita; Kunitada Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

9.  BCL3 acts as a negative regulator of transcription from the human T-cell leukemia virus type 1 long terminal repeat through interactions with TORC3.

Authors:  Takayuki Hishiki; Takayuki Ohshima; Takeshi Ego; Kunitada Shimotohno
Journal:  J Biol Chem       Date:  2007-07-20       Impact factor: 5.157

10.  Individual CREB-target genes dictate usage of distinct cAMP-responsive coactivation mechanisms.

Authors:  Wu Xu; Lawryn H Kasper; Stephanie Lerach; Trushar Jeevan; Paul K Brindle
Journal:  EMBO J       Date:  2007-05-24       Impact factor: 11.598

View more
  22 in total

1.  Identification and characterization of CCAAT enhancer-binding protein (C/EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent membrane protein 1.

Authors:  Chieko Noda; Takayuki Murata; Teru Kanda; Hironori Yoshiyama; Atsuko Sugimoto; Daisuke Kawashima; Shinichi Saito; Hiroki Isomura; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2011-10-19       Impact factor: 5.157

2.  Tetrameric ring formation of Epstein-Barr virus polymerase processivity factor is crucial for viral replication.

Authors:  Sanae Nakayama; Takayuki Murata; Yoshihiro Yasui; Kazutaka Murayama; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.

Authors:  Takayuki Murata; Yohei Narita; Atsuko Sugimoto; Daisuke Kawashima; Teru Kanda; Tatsuya Tsurumi
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

4.  Identifying the Cellular Interactome of Epstein-Barr Virus Lytic Regulator Zta Reveals Cellular Targets Contributing to Viral Replication.

Authors:  Yaqi Zhou; Kate Heesom; Kay Osborn; Rajaei AlMohammed; Steve M Sweet; Alison J Sinclair
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

5.  Screening of the Human Kinome Identifies MSK1/2-CREB1 as an Essential Pathway Mediating Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication during Primary Infection.

Authors:  Fan Cheng; Tanvee Vinod Sawant; Ke Lan; Chun Lu; Jae U Jung; Shou-Jiang Gao
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

6.  Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.

Authors:  Umama Z Siddiqi; Anup S Vaidya; Xinliu Li; Edyta Marcon; Sai Wah Tsao; Jack Greenblatt; Lori Frappier
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

7.  The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli.

Authors:  Stacy R Hagemeier; Elizabeth A Barlow; Qiao Meng; Shannon C Kenney
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

8.  Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase.

Authors:  Takayuki Murata; Naoe Hotta; Shigenori Toyama; Sanae Nakayama; Shigeki Chiba; Hiroki Isomura; Takayuki Ohshima; Teru Kanda; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

9.  Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.

Authors:  Takayuki Murata; Yutaka Kondo; Atsuko Sugimoto; Daisuke Kawashima; Shinichi Saito; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Virol       Date:  2012-02-22       Impact factor: 5.103

10.  Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor.

Authors:  Takayuki Murata; Chieko Noda; Yohei Narita; Takahiro Watanabe; Masahiro Yoshida; Keiji Ashio; Yoshitaka Sato; Fumi Goshima; Teru Kanda; Hironori Yoshiyama; Tatsuya Tsurumi; Hiroshi Kimura
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.